| Expert opinion on tilarginine in the treatment of shock. | |
| | |
MedLine Citation:
|
PMID: 18808317 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Tilarginine is L-N-monomethyl arginine (L-NMMA) or N(G)-monomethyl-L-arginine HCL, a non-selective inhibitor of nitric oxide synthase (NOS), which has been studied in the treatment of septic shock and cardiogenic shock complicating myocardial infarction. Despite strong evidence that excessive nitric oxide (NO) production plays a pivotal role in the pathogenesis of septic shock and may contribute to the pathogenesis of cardiogenic shock complicating myocardial infarction, outcome studies in these two disorders have proved disappointing. L-NMMA therapy was associated with an excess mortality, particularly at doses > 5 mg/(kg h), in septic shock whereas the effects of a lower dose (1 mg/(kg h)) in cardiogenic shock complicating myocardial infarction were neutral. The excess mortality in patients with septic shock was almost certainly the result of unfavourable haemodynamic changes induced by L-NMMA (decreased cardiac output, increased pulmonary vascular resistance and reduced tissue oxygen delivery) whereas the lack of benefit in patients with cardiogenic shock complicating myocardial infarction may have been because the dose of L-NMMA was too low. Further studies of L-NMMA at doses < 5 mg/(kg h) in conjunction with inotrope support may produce more beneficial results. Conversely, the use of a selective inducible NOS inhibitor to reduce the pathological effects of excessive NO production although leaving the beneficial effects of vascular NO production by endothelial NOS unaltered may prove to be of value. |
| | |
Authors:
|
Laurence Guy Howes; Divina Gracila Brillante |
Related Documents
:
|
10853217 - Vasopressin effective in reversing catecholamine-resistant vasodilatory shock. 21173507 - Angiography is the gold standard and objective evidence of myocardial ischemia is manda... 1078977 - Acute severe cardiac failure complicating myocardial infarction. experience with 100 pa... 8996417 - Difference in countries' use of resources and clinical outcome for patients with cardio... 433737 - Postpartum cardiac failure--heart failure due to volume overload? 3985927 - Nifedipine limits infarct size for 24 hours in closed chest coronary embolized dogs. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on investigational drugs Volume: 17 ISSN: 1744-7658 ISO Abbreviation: Expert Opin Investig Drugs Publication Date: 2008 Oct |
Date Detail:
|
Created Date: 2008-09-23 Completed Date: 2008-12-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9434197 Medline TA: Expert Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 1573-80 Citation Subset: IM |
Affiliation:
|
Griffith University and Bond University Medical Schools, Gold Coast Hospital, Department of Pharmacology and Therapeutics, Nerang St, Southport, Queensland 4215, Australia. laurie_howes@health.qld.gov.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Enzyme Inhibitors / therapeutic use* Heart / drug effects Humans Nitric Oxide / physiology Nitric Oxide Synthase / antagonists & inhibitors* Shock, Cardiogenic / drug therapy* Shock, Septic / drug therapy* Sympathetic Nervous System / drug effects omega-N-Methylarginine / pharmacology, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Enzyme Inhibitors; 10102-43-9/Nitric Oxide; 17035-90-4/omega-N-Methylarginine; EC 1.14.13.39/Nitric Oxide Synthase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prolonged-release melatonin for the treatment of insomnia in patients over 55 years.
Next Document: LB80380: a promising new drug for the treatment of chronic hepatitis B.